Skip to main content
SpringerLink
Log in

New doxorubicin nanocarriers based on cyclodextrins

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Polymeric nanoparticles and fibrin gels (FBGs) are attractive biomaterials for local delivery of a variety of biotherapeutic agents, from drugs to proteins. We combined these different drug delivery approaches by preparing nanoparticle-loaded FBGs characterized by their intrinsic features of drug delivery rate and antiproliferative/apoptotic activities. Inclusion complexes of doxorubicin (DOXO) with oligomeric β-cyclodextrins (oCyD) functionalized with different functional groups were studied. These nanocarriers were able to interact with FBGs as shown by a decreased release rate of DOXO. One of these complexes, oCyDNH2/DOXO, demonstrated good antiproliferative and apoptotic activity in vitro, reflecting a higher drug uptake by cells. As hypothesized, the nanocarrier/FBG complexes showed a lower drug release rate than similar FBGs loaded with the corresponding non-functionalized oCyD/DOXO. Taken together, our results provide experimental evidence that oCyDNH2/DOXO complexes may be useful components in enhanced FBGs and further build support for the great promise these complex molecules hold for clinical use in localized anticancer therapy of inoperable or surgically removable tumors of different histological origin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gidwani B, Vyas A (2014) Synthesis, characterization and application of epichlorohydrin-β-cyclodextrin polymer. Colloids Surf B 114:130–137

    Article  CAS  Google Scholar 

  2. Hu C-MJ, Fang RH, Luk BT, Zhang L (2014) Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies. Nano 6:65–75

    CAS  Google Scholar 

  3. Ruiz-Esparza GU, Wu S, Segura-Ibarra V, Cara FE, Evans KW, Milosevic M, Ziemys A, Kojic M, Meric-Bernstam F, Ferrari M, Blanco E (2014) Polymer nanoparticles encased in a Cyclodextrin Complex Shell for potential site- and sequence-specific drug release. Adv Funct Mater 24:4753–4761

    Article  CAS  Google Scholar 

  4. Oliveri V, D’Agata R, Giglio V, Spoto G, Vecchio G (2013) Cyclodextrin-functionalised gold nanoparticles via streptavidin: a supramolecular approach. Supramol Chem 25:465–473

    Article  CAS  Google Scholar 

  5. Swaminathan S, Cavalli R, Trotta F (2016) Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapuetics development. WIREs Nanomed Nanobiotechnol 8:579–601

    Article  CAS  Google Scholar 

  6. Oliveri G, Bellia F, Vecchio G (2017) Cyclodextrin nanoparticles bearing 8-hydroxyquinoline ligands as multifunctional biomaterials. Chem Eur J. doi:10.1002/chem.201700031

    Article  PubMed  Google Scholar 

  7. Anand R, Malanga M, Manet I, Manoli F, Tuza K, Aykac A, Ladaviere C, Fenyvesi E, Vargas-Berenguel A, Gref R, Monti S (2013) Citric acid-γ-cyclodextrin crosslinked oligomers as carriers for doxorubicin delivery. Photochem Photobiol Sci 12:1841–1854

    Article  CAS  Google Scholar 

  8. Folch-Cano C, Yazdani-Pedram M, Olea-Azar C (2014) Inclusion and functionalization of polymers with cyclodextrins: current applications and future prospects. Molecules 19:14066–14079

    Article  Google Scholar 

  9. Heidel JD, Schluep T (2012) Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. J Drug Deliv ID 262731:1–17

    Google Scholar 

  10. Avnesh S, Thakor MD, Sanjiv S, Gambhir MD (2013) Nanooncology: the future of cancer diagnosis and therapy. CA Cancer J Clin 63:395–418

    Article  Google Scholar 

  11. Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 18:456–468

    Article  CAS  Google Scholar 

  12. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–1670

    Article  CAS  Google Scholar 

  13. Giglio V, Viale M, Monticone M, Aura AM, Spoto G, Natile G, Intini FP, Vecchio G (2016) Cyclodextrin polymers as carries for the platinum-based anticancer agent LA-12. RSC Adv 6:12461–12466

    Article  CAS  Google Scholar 

  14. Kanwar JR, Long BM, Kanwar RK (2011) The use of cyclodextrins nanoparticles for oral delivery. Curr Med Chem 18:2079–2085

    Article  CAS  Google Scholar 

  15. Longmire M, Choyke PL, Kobayashi H (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (London) 3:703–717

    Article  CAS  Google Scholar 

  16. Dal Ben D, Palumbo M, Zagotto G, Capranico G, Moro S (2007) DNA topoisomerase II structures and anthracyclines activity: insights into ternary complex formation. Curr Pharm Des 13:2766–2780

    Article  CAS  Google Scholar 

  17. Grosse PY, Bressolle F, Pinguet F (1997) Methyl-beta-cyclodextrin in HL-60 parental and multidrug-resistant cancer cell lines: effect on the cytotoxic activity and intracellular accumulation of doxorubicin. Cancer Chemother Pharmacol 40:489–494

    Article  CAS  Google Scholar 

  18. Al-Omar A, Abdou S, De Robertis L, Marsura A, Finance C (1999) Complexation study and anticellular activity enhancement by doxorubicin-cyclodextrin complexes on a multidrug-resistant adenocarcinoma cell line. Bioorg Med Chem Lett 9:1115–1120

    Article  CAS  Google Scholar 

  19. Gil ES, Li J, Xiao H, Lowe TL (2009) Quaternary ammonium -cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier. Biomacromolecules 10:505–516

    Article  CAS  Google Scholar 

  20. Bozzuto G, Molinari A (2015) Liposomes as nanomedical devices. Int J Nanomedicine 10:975–999

    Article  CAS  Google Scholar 

  21. Jhaveri MS, Rait AS, Chung K-N, Trepel JB, Chang EH (2004) Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 3:1505–1512

    CAS  PubMed  Google Scholar 

  22. Giglio V, Sgarlata C, Vecchio G (2015) Novel amino-cyclodextrin cross-linked oligomer as efficient carrier for anionic drugs: a spectroscopicand nanocalorimetric investigation. RSC Adv 5:16664–16671

    Article  CAS  Google Scholar 

  23. Dinges HP, Redl H, Thurnher M, Schiesser A, Schlag G (1986) Morphometric studies on wound healing after systemic administration of Adriamycin and local application of fibrin sealant: application of a new wound healing model using spongiosa implants. Pathol Res Pract 181:746–754

    Article  CAS  Google Scholar 

  24. Kitazawa H, Sato H, Adachi I, Masuko Y, Horikoshi I (1997) Microdialysis assessment of fibrin glue containing sodium alginate for local delivery of doxorubicin in tumor bearing rats. Biol Pharm Bull 20:278–281

    Article  CAS  Google Scholar 

  25. Yoshida H, Yamaoka Y, Shinoyama M, Kamiya A (2000) Novel drug delivery system using autologous fibrin glue-release properties of anti-cancer drugs. Biol Pharm Bull 23:371–374

    Article  CAS  Google Scholar 

  26. Viale M, Rossi M, Russo E, Cilli M, Aprile A, Profumo A, Santi P, Fenoglio C, Cafaggi S, Rocco M (2015) Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model. Invest New Drugs 33:1151–1116

    Article  CAS  Google Scholar 

  27. Novi M, Ottone M, Dell’Erba C, Barbieri F, Chiavarina B, Maccagno M, Viale M (2004) 1,4-Bis(1-naphtyl)-2,3-dinitro-1,3-butadiene a novel anticancer compound effective against tumor cell lines characterized by different mechanisms of resistance. Oncol Rep 12:91–96

    CAS  PubMed  Google Scholar 

  28. Dell’Erba C, Chiavarina B, Fenoglio C, Petrillo G, Cordazzo C, Boncompagni E, Spinelli D, Ognio E, Aiello C, Mariggiò MA, Viale M (2005) Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1, 4-bis (1-naphthyl)-2, 3-dinitro-1, 3-butadiene in gastrointestinal tumor cell lines and preliminary evaluation of its toxicity in vivo. Pharmacol Res 52:271–282

    Article  Google Scholar 

  29. Etrych T, Chytil P, Jelínková M, Ríhová B, Ulbrich K (2002) Synthesis of HPMA copolymers containing doxorubicin bound via a hydrazone linkage. Effect of spacer on drug release and in vitro cytotoxicity. Macromol Biosci 2:43–52

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was in part carried out thanks to the grant 2012.1020, Compagnia di San Paolo, Turin, Italy (to Maurizio Viale). We are indebted to Dr. C.G. Binnie, Ph.D. (Carrboro, NC, USA) for proof reading and language editing of the manuscript.

Author information

Authors and Affiliations

  1. IRCCS A.O.U. San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, U.O.C. Bioterapie, L.go R. Benzi 10, 16132, Genoa, Italy

    Maurizio Viale, Massimiliano Monticone & Irena Maric

  2. Dipartimento di Scienze Chimiche, Università di Catania, Viale A. Doria 6, 95125, Catania, Italy

    Valentina Giglio & Graziella Vecchio

  3. Dipartimento di Farmacia – Scienze del Farmaco, Università degli Studi di Bari ‘Aldo Moro’, Via E. Orabona 4, 70126, Bari, Italy

    Giovanni Lentini

  4. IRCCS A.O.U. San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, U.O.S. Biopolimeri e Proteomica, L.go R. Benzi 10, 16132, Genoa, Italy

    Mattia Rocco

Authors
  1. Maurizio Viale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valentina Giglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Massimiliano Monticone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Irena Maric
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giovanni Lentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mattia Rocco
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Graziella Vecchio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maurizio Viale.

Ethics declarations

Conflict of interest

Maurizio Viale declares that he has no conflict of interest. Valentina Giglio declares that she has no conflict of interest. Massimiliano Monticone declares that he has no conflict of interest. Irena Maric declares that she has no conflict of interest. Giovanni Lentini declares that he has no conflict of interest. Mattia Rocco declares that he has no conflict of interest. Graziella Vecchio declares that she has no conflict of interest.

Funding

This work was supported by grant 2012.1020, Compagnia di San Paolo, Turin, Italy (to Maurizio Viale).

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Dedicated to the memory of Dr. Carmela Spatafora

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Viale, M., Giglio, V., Monticone, M. et al. New doxorubicin nanocarriers based on cyclodextrins. Invest New Drugs 35, 539–544 (2017). https://doi.org/10.1007/s10637-017-0461-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-017-0461-0

Keywords

Search

Navigation